General Information:

Id: 5,678 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
MODY, type VI - [OMIM]
Rattus norvegicus
BTO:0002135 INS-1 cell
article
Reference: Kim HS et al.(2008) Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression Biochem. Biophys. Res. Commun. 367: 623-629 [PMID: 18191635]

Interaction Information:

Comment Peroxisome proliferator-activated receptor (PPAR)-gamma is a member of the nuclear receptor superfamily, and its ligands, the thiazolidinediones, might directly stimulate insulin release and insulin synthesis in pancreatic beta-cells. In the present study, the effects of rosiglitazone (RGZ) on insulin release and synthesis in pancreatic beta-cell (INS-1) were examined. Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression.
Formal Description
Interaction-ID: 53962

drug/chemical compound

Rosiglitazone

increases_expression of

gene/protein

SLC2A2

Drugbank entries Show/Hide entries for Rosiglitazone or SLC2A2